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§University of Oslo, Oslo, Norway.BACKGROUND Patients with Jervell and Lange-Nielsen syndrome
(JLNS) exhibit severe phenotypes that are characterized by
congenital deafness, very long QT intervals, and high risk of life-
threatening arrhythmias. Current treatment strategies include
high doses of beta-blocker medication, left cardiac sympathetic
denervation, and ICD placement, which is challenging in young
children.
OBJECTIVE The purpose of this study was to evaluate the safety
and effect of pacing in addition to beta-blocker treatment in
children with JLNS.
METHODS All genetically conﬁrmed patients with JLNS born since
1999 in Norway were included in the study. Data on history of long
QT syndrome–related symptoms, QT interval, and beta-blocker and
pacemaker treatment were recorded.
RESULTS A total of 9 patients with QT intervals ranging from 510
to 660 ms were identiﬁed. Eight patients developed long QT
syndrome–related symptoms, and 1 patient died before diagnosis.
The survivors received beta-blocker medication. Seven patients alsoAddress reprint requests and correspondence: Dr. Kristina Haugaa,
Department of Cardiology, Oslo University Hospital, Rikshospitalet, Post-
boks 4950 Nydalen, 0424 Oslo, Norway. E-mail address: kristina.hau-
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1547-5271/$-see front matter B 2016 The Authors. Published by Elsevier Inc. on
10.1016/j.hrthm.2016.07.020received a pacemaker; 1 had a ventricular lead and 6 had atrial
leads. The patient with the ventricular lead died during follow-up.
The 6 patients with atrial leads survived without events at a mean
follow-up of 6.9 years after pacemaker implantation. Two patients
received prophylactic upgrade to a 2-chamber ICD.
CONCLUSION No arrhythmic events occurred in 6 very young JLNS
patients who received atrial pacing in combination with increased
doses of beta-blockers during 7-year follow-up. If conﬁrmed in
additional patients, this treatment strategy may prevent life-
threatening arrhythmias in this high-risk patient group and may
act as a bridge to insertion of a 2-chamber ICD when left cardiac
sympathetic denervation is not available.
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Jervell and Lange-Nielsen syndrome (JLNS)1 is an autoso-
mal recessive form of the long QT syndrome (LQTS), which
is caused by mutations in the KCNQ12,3 or KCNE14 gene.
JLNS is characterized by congenital deafness and severe
cardiac phenotypes with very long QT intervals, high risk of
life-threatening ventricular arrhythmias, and breakthroughs
of arrhythmias despite beta-blocker treatment.5,6 We pre-
viously reported a high prevalence of JLNS in Norway7 due
to founder mutations.8 A small subgroup of patients withmutations on both KCNQ1 alleles and prolonged QT
intervals do not present with deafness but appear to have a
similar risk of cardiac events as JLNS patients.9
Beta-blocker medication is the mainstay therapy in
patients with LQTS, and high doses are often required to
suppress ventricular arrhythmias. High doses of beta-blocker
medication are associated with several side effects, the most
important being bradycardia. Pacemaker implantation in
patients with severe bradycardia may help them tolerate the
medical treatment. Furthermore, pacemaker therapy with
relatively rapid pacing can also prevent torsades de pointes
ventricular arrhythmia and suppress electrical storms in
acquired10,11 and congenital LQTS.12
ICD placement has been recommended in children with
JLNS, particularly after 10 years of age.5 ICD therapy isbehalf of Heart Rhythm Society. All rights reserved. http://dx.doi.org/
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complicated by lead problems due to the patient’s small body
size, growth, and the prospect of lifelong ICD therapy. Thus,
when beta-blocker therapy is not sufﬁcient in very young
JLNS patients, the choice of therapy is challenging. Left
cardiac sympathetic denervation (LCSD) has been reported
as an option.13,14 However, this surgery is not available in all
countries, and the experience with alternative therapies in
this patient group is limited.
Ten years ago, we were confronted with a series of young
JLNS patients who had cardiac events despite beta-blocking
therapy in addition to young JLNS patients in whom an
effective beta-blocker dose could not be achieved because of
bradycardia. We were concerned about the high complica-
tion rate after ICD insertion in children in addition to the risk
of appropriate and inappropriate shocks and the inherent risk
of triggering life-threatening electrical storms in these
patients.15
Consistent with the above-mentioned rationale for pace-
maker therapy, we decided to implant pacemakers in these
JLNS patients to achieve higher doses of beta-blocker
medication. In this study, we report the clinical character-
istics, treatment (both medical and with implantable devi-
ces), and outcome of young patients with JLNS.
Methods
Recruitment of study population
All genetically conﬁrmed patients with JLNS in Norway
born after January 1, 1999, were included in this retrospec-
tive study. Recruitment was facilitated by the start of
nationwide genetic testing for LQTS at our center. In the
same time period, implementation of a national pediatric
cochlear implant program was initiated and conducted
from our center, which included children with congenital
deafness.
Genetic testing was performed as part of the diagnostic
workup and executed as previously described.8 Only sub-
jects with homozygous or compound heterozygous con-
ﬁrmed pathogenic mutations were included.
Data collection
The medical records of all patients included in the study were
retrospectively scrutinized for data, including age, height,
and weight at diagnosis and during follow-up. LQTS-related
cardiac events were classiﬁed as syncope when there was a
loss of consciousness alone; as seizures with movements
reminiscent of convulsions; as life-threatening attacks when
the measures to revival were started; and as torsades de
pointes when documented with ECG monitoring. From 12-
lead ECGs, the QT intervals were measured from the start of
Q to the end of the T wave and corrected for heart rate using
the Bazett formula.16 Beta-blocker medication and dosages
were recorded at initiation, at pacemaker implantation, and
during follow-up. Medication dosages were reported accord-
ing to body weight. We recorded age at device implantation,
heart rate and programming modus, complications due todevice implantation, and indications for device replacement.
Routine follow-up included echocardiography to exclude
pacing-induced cardiomyopathy, Holter recordings to con-
ﬁrm regular pacemaker function and adequate beta-blocker
treatment, and treadmill tests in older children.
Ethics
The study was classiﬁed as a quality control study and was
approved by the review board of Oslo University Hospital.
Statistical analysis
Group data are presented as mean ± SD or median (range).
For QT intervals before and after atrial pacing, a paired T test
was used. Because of the low number of participants, no
further statistical analyses were performed.
Results
Clinical characteristics
The study included 9 genotype-positive patients. All patients
were homozygous or compound heterozygous for patho-
genic mutations in the KCNQ1 gene. Age at diagnosis was
1.7 ± 1.6 years [median 1.1 (range 0–3.3) years], and 6 of 9
(66%) were females (Table 1). Four of 9 patients (44%) were
diagnosed a few days after birth as a result of low heart rates
and very long QT intervals. In 1 patient, the genetic status of
the parents was known because an elder sibling had JLNS.
The remaining 5 patients were diagnosed with LQTS
between 2 and 3 years of age. In cases 8 and 9, the diagnosis
was not known at the time of cochlear implantation. In case
9, a deaf 3-year-old boy had a diagnosis of JLNS that was
genetically conﬁrmed postmortem, despite suffering 4100
events from the age of 14 months, including life-threatening
events that were misdiagnosed as seizures and breath-
holding spells. This led to a change in policy in our
otolaryngology department and a screening program with
ECG before cochlear implantation was established. Case 2
was diagnosed by routine ECG before cochlear implantation.
Eight of 9 patients (89%) received cochlear implants at a
median age of 2.1 (range 0.3–3.2) years and have been
previously reported in studies evaluating the causes of
hearing impairment7 and aspects regarding cochlear implan-
tation.17 One patient (case 6), who was compound hetero-
zygous for 2 pathogenic mutations in the KCNQ1 gene, had
only discrete high-frequency hearing loss but a very long QT
interval. Overall, these 9 children were followed for an
average of 7.5 ± 5.0 years [median 9.3 (range 0.6–14.2)
years] from the ﬁrst contact with our institution and follow-
up, which covered a total of 67.9 patient-years.
ECG and QT interval
QTc was 590 ± 50 ms, median was 600 ms (range 510–660
ms), and ECG in 7 of 9 patients (77%) showed T-wave
alternans (Table 2). Figure 1 shows the ECG of case 6 before
(panel A) and after (panel B) pacing. QTc decreased in the 6
patients with atrial pacing, from 610 ± 60 ms to 490 ± 10 ms
(P o.01).
Table 1 Summary of the cases
Age (years)
Case Sex Gene defect†
At long QT
syndrome
diagnosis
At cochlear
implantation
At pacemaker
implantation
At last
follow-up
1 F c.572delTGCGC (p.R192Cfs*91)/c.572delTGCGC (p.R192Cfs*91) 0.0 0.7 6.4 9.7 (a)
2 F c.572delTGCGC (p.R192Cfs*91)/c.572delTGCGC (p.R192Cfs*91) 3.0 3.2 NI 10.3 (a)
3 F c.572delTGCGC (p.R192Cfs*91)/c.1552C4T (p.R518X) 0.0 2.3 7.5 15.2 (a)
4 M c.572delTGCGC (p.R192Cfs*91)/c.1552C4T (p.R518X) 0.0 0.3 0.0 9.4 (a)
5 M c.572delTGCGC (p.R192Cfs*91)/c.1588C4T (p.Q530X) 2.2 2.3 2.3 2.7 (d)
6 F c.783G4C (p.E261D)/c.1588C4T (p.Q530X) 3.3 NI 3.8 7.0 (a)
7 F c.1588C4T (p.Q530X)/c.1588C4T (p.Q530X) 0.0 0.5 0.0 9.3 (a)
8 F c.1588C4T (p.Q530X)/c.1588C4T (p.Q530X) 3.3 1.9 5.3 14.0 (a)
9 M c.1588C4T (p.Q530X)/c.1760C4T (p.T587M) Postmortem 2.5 NI 3.2 (d)
a ¼ alive; d ¼ dead; NI ¼ not implanted.
†KCNQ1 reference sequence: NM_000218.2.
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All patients, except case 9, who died before diagnosis of
JLNS, were treated with beta-blockers at the highest possible
dose considered by the treating physician (Table 2). Propra-
nolol was usually divided into 3 doses, and metoprolol and
nadolol into 2 daily doses. In 3 patients (cases 4, 7, and 8),
sufﬁcient beta-blocker dosages were not reached before
pacemaker implantation. Case 4 had a documented minimum
heart rate of 40 bpm before initiation of beta-blocker and
several symptomatic bradycardiac episodes between 40 and
50 bpm combined with T-wave alternans on propranolol 0.3
mg/kg. Case 7 had a documented sinus arrest with a long
pause when beta-blocker therapy was initiated. Case 8 was
symptomatic with fatigue and had a low mean heart rate on
Holter (below 2 SD for age) and an insufﬁcient chronotropic
response; increase of beta-blocker was refused by the
parents. Another 3 patients had syncopal events on beta-
blocker before pacemaker implantation. We were able to
increase beta-blocker treatment in 7 of 9 patients (78%) after
pacemaker implantation. In 1 patient (case 5), the daily
metoprolol dose was increased from 3.3 mg/kg to 6.2 mg/kg
after pacemaker implantation. In the other patients, median
daily propranolol dose was 1.2 mg/kg (range 0.3–3.1 mg/kg)
before and 3.6 mg/kg (range 2.2–5.7 mg/kg) after pacemakerTable 2 Symptoms, ECG, and beta-blocker dosage before pacemaker im
initial presentation
Case Symptoms Heart rate
Range
QTc (ms)
1 Bradycardia, syncope 60 580–660
2 No symptoms 80 510–550
3 Bradycardia, syncope 53 570–640
4 Bradycardia 94 520–570
5 Seizures, life-threatening attacks 65 560–580
6 Syncope 70 640–700
7 Bradycardia, asystole 97 630–670
8 Seizures 80 490–540
9 Seizures, life-threatening attacks 100 590–670
*No beta-blockade at the time of ECG, later propranolol 3 mg/kg/d.implantation. Beta-blocker therapy was subsequently
changed to nadolol in these patients. Daily median nadolol
dosage at the most recent visits was 2.1 mg/kg (range 1.5–2.4
mg/kg), and dosages were further increased in patients with
the lowest doses at the last visit according to weight gain.
One patient, who was asymptomatic but was diagnosed by
ECG screening (case 2), received only beta-blockers and no
pacemaker implantation and remained asymptomatic on
propranolol 3 mg/kg/d. Case 5 remained on metoprolol and
had cardiac events with documented torsades before and
after pacemaker implantation.Pacemaker therapy, complications, and follow-up
Indications for pacemaker therapy were cardiac events
despite beta-blocker therapy and intolerable bradycardia
and pauses at insufﬁcient beta-blocker doses. In all, 7 of 9
children (78%) received a single-chamber pacemaker in
addition to beta-blocker treatment at a median age of 3.8
years (range 0–7.5 years). Six patients received atrial leads,
and 1 child (case 5) received a ventricular lead (Table 3).
Upgrades from a unipolar epicardial to a bipolar transvenous
atrial lead were performed in 2 children at the ages of 6.8 and
7.2 years. Upgrades from a transvenous atrial pacemaker to aplantation, of case 1 immediately before death, and of case 5 at
T-wave
alternans
Mean
QTc (ms) Beta-blocker
Dosage
(mg/kg/d)
Yes 600 Propranolol 2.9
No 530 None*
Yes 620 Propranolol 3.1
Yes 550 Propranolol 0.3
Yes 580 Metoprolol 3.3
Yes 660 Metoprolol 1.7
Yes 630 Propranolol 1,1
No 510 Propranolol 1.2
Yes 630 None
590 (median 600)
Figure 1 Twelve-lead ECG of case 6 before (A) and after (B) pacemaker implantation. A: Note the loss of sinus rhythm and T-wave alternans with variable
extremely long QT intervals. Mean QTc ¼ 660 ms. B: With atrial pacing, the rhythm is regular, and QTc ¼ 520 ms.
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of 11.8 and 14.7 years. Complications due to lead displace-
ments were observed in 2 patients (Table 3). The patient with
the ventricular lead (case 5) had another life-threatening
event with torsades de pointes arrhythmia during intermittent
pacing due to lead dislocation 8 weeks after pacemaker
implantation. Although the lead was revised, the child died
3 months later during a fatal event. None of the patients with
atrial leads had any cardiac event during mean follow-up
of 6.9 ± 2.9 years after pacemaker implantation. One girlTable 3 Initial pacemaker implantation and reinterventions
Case Leads Pacing mode
1 Bipolar transvenous AAIR
3 Bipolar transvenous AAIR
4 Unipolar epicardial AAIR
5 Unipolar transvenous VVI
6 Bipolar transvenous AAIR
7 Unipolar epicardial AAIR
8 Bipolar transvenous AAIR
ICD ¼ implantable cardioverter–deﬁbrillator.(case 1) also had diabetes type I and was using an insulin
pump. During an episode with gastroenteritis, she had a
hypoglycemic fainting episode, which was conﬁrmed by
blood glucose samples.
The pacemaker of case 5 was ﬁrst programmed in the VVI
mode with a rate of 80 bpm and later in VVIRmode 100 to 130
bpm. The pacemakers of the 2 infants who received epicardial
atrial leads were programmed in the AAI mode with rates from
115 to 125 bpm. After 1 year of age, the pacemakers of all
children with atrial leads were programmed in the AAIR modeComplications and further interventions
Electrode dislocation at 3 days revised
Upgrade to 2-chamber ICD at age 14.7 years
Upgrade to bipolar transvenous lead at age 7.2 years
Electrode dislocation at 8 weeks revised, death at age 2.7 years
None
Upgrade to bipolar transvenous lead at age 6.8 years
Upgrade to 2-chamber ICD at age 11.8 years
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maximum rate below the rate of AV conduction block. The
mean heart rate of the 6 atrial paced patients on the latest Holter
recording was 88 ± 4 bpm. Holter recordings revealed
occasional premature beats, occasional blocked beats during
deep sleep at night, occasional far-ﬁeld sensing of the
ventricular signal with delayed atrial pacing, occasional under-
sensing of sinus rhythmwith competitive atrial pacing, and in 1
case with a unipolar epicardial atrial lead, a pause that could
only be explained by far-ﬁeld sensing of the T wave. The latter
was resolved by an upgrade to a bipolar transvenous lead.
Discussion
This study showed that 6 JLNS patients treated with a
combination of an atrial pacemaker and beta-blocker
remained free from arrhythmic events during mean follow-
up of 6.9 years after pacemaker implantation. One male
patient with ventricular pacing died during the follow-up
period. These results may indicate that the combination of
atrial pacing and beta-blocker therapy may be a potential
alternative strategy in very young JLNS patients as a bridge
to ICD placement.
Beta-blocker therapy in LQTS
All patients in our study, except the 1 male patient who died
before diagnosis was made, were treated with beta-blocking
medication during the follow-up period. Beta-blocker treat-
ment is efﬁcient as antiarrhythmic therapy in patients with
LQTS, particularly LQTS type 1.18 The effect appears to
vary between different beta-blockers in the treatment of
LQTS,19 and metoprolol is considered less efﬁcient than
propranolol or nadolol.19,20 The limited number of patients
in our study did not allow for conclusions regarding the
effectiveness of different beta-blockers. Regardless of the
type of beta-blocker, a recurrence rate with beta-blocker of
51% to 85% in patients with JLNS has been reported in large
surveys.5,6,20 We also observed several recurrent events in
patients on beta-blocker before pacemaker implantation,
although 3 of these patients were on insufﬁcient beta-blocker
dosages. We were able to increase the doses of beta-blockers
after pacemaker implantation, and we preferred nadolol
twice daily in older children instead of propranolol three
times per day because compliance is an important factor in
beta-blocker effectiveness.18
Rationale for pacemaker therapy in LQTS
Pacing at higher rates was reported to prevent torsades de
pointes ventricular tachycardia in drug-induced LQTS 5
decades ago.10 Additional case reports have indicated that
pacing prevented ventricular arrhythmias in congenital
LQTS.12,21 Four additional studies published from 1987 to
1999,22–25 which included 8 to 37 patients, showed the
potential beneﬁt of pacing when given in addition to beta-
blocker therapy in high-risk patients with LQTS.24,25 How-
ever, these studies had partly overlapping patients and
consisted of heterogeneous patient populations, includingchildren and adults, LQTS patients with an unknown
genotype of LQTS, and those with varying frequencies of
AV block.
Importantly, previous studies provided no clear indication
of optimal pacing mode, although breakthroughs of arrhyth-
mias on beta-blocker therapy were abolished by switching
from ventricular to atrial pacing in an LQTS case report from
1997.21 Our study indicated that AAI pacing may be
preferable when possible, and ventricular pacing should be
avoided. Right ventricular pacing may potentially induce
signiﬁcant cardiomyopathy, particularly at high pacing rates.
Furthermore, ventricular pacing without AV synchronicity
may result in the next AV conducted sinus beat occurring in
the vulnerable interval and triggering arrhythmias. Finally,
the abnormal T waves in LQTS commonly result in T-wave
oversensing, which may result in incorrect pacing inhibi-
tion.26 Thus, VVI pacing in LQTS is not a neutral inter-
vention, and some of the features useful in a normal pacing
population might be harmful in LQTS patients.27 Sporadic
undersensing or oversensing of ventricular activity can be
deleterious in a LQTS patient, but it is often of minor
concern in a normal pacemaker patient. Malfunction of
pacing leads has been associated with major problems, as
also observed in our case 4.24,25 We monitored our JLNS
population by performing regular Holter recordings to ensure
that every beat was correctly paced and conducted. AAI
pacing is preferred as long as 1:1 conduction is ensured.23
Thus, we tested AV conduction in each case at higher rates,
and maximum pacing rate was established clearly below the
rate of AV conduction block. Furthermore, the sensing
threshold and blanking and refractory intervals were care-
fully programmed to avoid undersensing and oversensing.Pacing rate
Aminimal heart rate between 60 and 80 bpm is considered to
prevent torsades de pointes arrhythmias.23,27,28 In this study,
we used pacing rates at 90 bpm during the day and 80 bpm
during the night in children41 year of age, and rates from
115 to 125 bpm in children ≤1 year of age. Pacing at higher
rates during exercise might reduce stress in LQTS type 1
patients,27 particularly when the intrinsic heart rate of the
patient is not increasing, either due to the lower heart rate in
these patients or the effects of beta-blockade. QTc decreased
in our 6 patients who were AAI paced. However, the
patients were older and received higher doses of beta-blocker
at ECG follow-up compared to baseline, limiting the
interpretation.
We believe that there probably is a dual mechanism of
beneﬁcial action in our patients: increased heart rate by atrial
pacing preventing ventricular arrhythmias and the possibility
of increasing antiarrhythmic beta-blocker medication. How-
ever, pacing at faster heart rates increases the risk of
tachycardia-induced cardiomyopathy. Unfortunately, the
maximal heart rate that can be used safely over longer
periods is unknown.27 We monitored heart rate by Holter
recordings and exercise tests with the aim of 100% atrial
2191Früh et al Atrial Pacing in High-Risk Long QT Syndromepacing and increased the beta-blocker dose when the intrinsic
rhythm exceeded the pacing rate. Furthermore, echocardiog-
raphy was performed regularly in all patients to exclude
pacing-induced cardiomyopathy.
Recurrent events and ICD therapy in very young
LQTS patients
During the follow-up period, we upgraded 2 of the patients
with atrial pacing to a dual-chamber ICD on primary
indication, after unchanged strategy with continuous AAIR
pacing and beta-blockade. They have been arrhythmia-free
during the follow-up period. Pacing in LQTS has been less
reported less frequently after 2002, most likely because of
the greater number of patients receiving an ICD. In 2010, 2
larger studies on ICD treatment in LQTS patients, including
children, were published.29,30 They reported high rates of
appropriate and inappropriate shocks and complications.
Data from JLNS patients,6 without providing any informa-
tion on age at ICD insertion, reported at least 1 appropriate
shock in 75% of the patients and multiple shocks in 63% of
the patients during follow-up of 4.9 years after ICD place-
ment. In 2006, Schwartz et al5 reported arrhythmia recur-
rences in 9 of 11 patients with a pacemaker and in 4 of 13
patients with an ICD, but also in 9 of 16 patients with LCSD.
Some of the patients had more than 1 additional therapy, thus
limiting comparisons to our study. Apart from these sum-
mary data, no data on arrhythmia recurrences and atrial
pacing in JLNS are available in some of the largest centers
worldwide. The very high risk of shocks highlights the fact
that ICD placement alone is not sufﬁcient to treat high-risk
LQTS patients, and all possible measures are necessary to
ensure event-free survival.31,32
Insertion of the ICD device is technically complicated in
very young children. The ICD is larger and heavier than a
pacemaker, and if an ICD is placed, a dual-chamber ICD
should be chosen to avoid ventricular pacing. In our study, 2
patients experienced complications with lead dislocations.
Further potential risks include infections, vascular compli-
cations, and device erosion, in addition to lead replacement
necessary because of growth. Implantation of an atrial
pacemaker involves simpler instrumentation and might, in
combination with increased doses of beta-blocker medica-
tion, serve as a bridge to dual-chamber ICD placement in
very young patients with JLNS or high-risk LQTS.
Further intervention to prevent events in high-risk LQTS
patients is LCSD.13,14 LCSD has been proposed as an
additional treatment and might also serve as a bridge to
ICD in young patients, particularly in case of bradycardia
and beta-blocker intolerance because LCSD does not lower
the heart rate.33,34 None of our patients underwent this
surgery.
Study limitations
All the JLNS patients in our study had mutations in the
KCNQ1 gene, which includes a higher risk compared to
patients with KCNE1 gene mutations.5 However, 6 of 9patients (67%) were female, and 5 of 6 patients (83%) were
female in the group with atrial pacing. Females are reported
to have a lower risk for life-threatening events,5,6 and gender
differences might have inﬂuenced the outcome.
Although this was a comparatively large single-center
study of JLNS patients, the study included a very limited
number of patients, and the study had a retrospective design.
Therefore, our conclusions are limited and preliminary, and
future studies are needed to conﬁrm our results.
No arrhythmic events occurred in 6 very young JLNS
patients with atrial pacing in combination with increased
doses of beta-blocker during 6.9 years of follow-up. The
concept of combining atrial pacing with adequate beta-
blocker therapy may act as a bridge for subsequent ICD
therapy in very young patients with high risk LQTS when
LCSD is not available.
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